Wave Life Sciences stock highlights WVE-007 obesity data

Published on 11/15/2026 at 13:32 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Wave Life Sciences stock highlighted WVE-007 data from its Phase 1 obesity trial on November 13. Six-month Phase 2a data are expected in 2027.

WVE-007 Development Milestones

Phase 1 results showed durable Activin E reductions and preserved lean mass in selected dose cohorts.
Wave expects six-month Phase 2a monotherapy data in 2027.
The company plans to integrate its maintenance trial with the ongoing WVE-007 and tirzepatide combination study.

Wave Life Sciences stock, WVE-007, obesity treatment, RNA medicines, clinical trial, Illustration mit AI erstellt.

Wave Life Sciences highlighted new clinical progress for its WVE-007 obesity candidate in a November 13, 2026 announcement carried by TradingView. The update covered Phase 1 findings presented around ObesityWeek 2026 and outlined the next development steps for the RNA-based treatment.

Phase 1 Data Support Further Testing

Wave said single-dose Activin E reductions in the 240 mg, 400 mg and 600 mg cohorts reached mean maximum levels of 82%, 84% and 88%, respectively. The company said WVE-007 remained generally well tolerated, with no treatment discontinuations or drug-related serious adverse events reported in the trial update.

Participants in the 240 mg cohort, which had the highest baseline body mass index among the groups, continued to show placebo-adjusted reductions in visceral fat, total fat and waist circumference while preserving lean mass one year after a single dose. Wave also said participants with higher baseline body mass and adiposity showed more pronounced treatment effects.

Phase 2a Timeline And Trial Design

The ongoing Phase 2a portion of the INLIGHT trial is evaluating WVE-007 in people with a body mass index of 35 to 50, with and without type 2 diabetes. The study measures body weight, waist circumference, body composition, liver fat, glycated hemoglobin and lipid levels. Wave expects to report six-month monotherapy data in 2027.

Wave is also running a Phase 2a trial that compares WVE-007 combined with weekly tirzepatide against tirzepatide alone. The company announced plans to integrate its maintenance clinical trial into that combination study, a step intended to improve operating efficiency and accelerate the delivery of data.